...
首页> 外文期刊>Saudi Pharmaceutical Journal >Formulation and in vitro evaluation of topical nanosponge-based gel containing butenafine for the treatment of fungal skin infection
【24h】

Formulation and in vitro evaluation of topical nanosponge-based gel containing butenafine for the treatment of fungal skin infection

机译:纯纳米盆凝胶的配方和体外评价含丁啡胺治疗真菌皮肤感染的凝胶

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In the current study, four formulae (BNS1-BNS4) of butenafine (BTF) loaded nanosponges (NS) were fabricated by solvent emulsification technology, using different concentration of ethyl cellulose (EC) and polyvinyl alcohol (PVA) as a rate retarding polymer and surfactant, respectively. Prepared NS were characterized for particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE) and drug loading (DL). Nanocarrier BNS3 was optimized based on the particle characterizations and drug encapsulation. It was further evaluated for physicochemical characterizations; FTIR, DSC, XRD and SEM. Selected NS BNS3 composed of BTF (100?mg), EC (200?mg) and 0.3% of PVA showed, PS (543?±?0.67?nm), PDI (0.330?±?0.02), ZP (?33.8?±?0.89?mV), ? (71.3?±?0.34%) and %DL (22.8?±?0.67%), respectively. Fabricated NS also revealed; polymer-drug compatibility, drug-encapsulation, non-crystalline state of the drug in the spherical NS as per the physicochemical evaluations. Optimized NS (BNS3) with equivalent amount of (1%, w/w or w/v) BTF was incorporated into the (1%, w/w or w/v) carbopol gel. BTF loaded NS based gel was then evaluated for viscosity, spreadability, flux, drug diffusion, antifungal, stability and skin irritation studies. BNS3 based topical gels exhibited a flux rate of 0.18 (mg/cm 2 .h), drug diffusion of 89.90?±?0.87% in 24?h with Higuchi model following anomalous non-Fickian drug release. The BNS3 based-gel could be effective against pathogenic fungal strains.
机译:在目前的研究中,通过溶剂乳化技术,使用不同浓度的乙基纤维素(EC)和聚乙烯醇(PVA)作为速率延迟聚合物和表面活性剂分别。制备的NS针对粒度(PS),多分散性指数(PDI),Zeta电位(ZP),熵效率(EE)和药物负载(DL)。基于颗粒表征和药物封装优化纳米载波BNS3。它进一步评估了物理化学特征; FTIR,DSC,XRD和SEM。选择的NS BNS3由BTF(100?Mg),EC(200?Mg)和0.3%的PVA显示,PS(543?±0.67?NM),PDI(0.330?±0.02),ZP(?33.8? ±0.89?mv),? (71.3?±0.34%)和%DL(22.8?±0.67%)。制造的NS也透露;根据物理化学评估,聚合物 - 药物相容性,药物封装,药物中药物中的非结晶状态。优化的NS(BNS3)具有等当量的(1%,w / w或w / v)btf掺入(1%,w / w或w / v)carbopol凝胶中。然后评估BTF的基于NS的凝胶,用于粘度,铺展性,助焊剂,药物扩散,抗真菌,稳定性和皮肤刺激性研究。基于BNS3的局部凝胶表现出0.18(mg / cm 2 .h)的通量速率,药物扩散为89.90°(24Ω·0.87%,在异常的非Fickian药物释放后的HIGUCHI模型。基于BNS3的凝胶可对致病性真菌菌株有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号